abstract IL-5 is the most potent activator of eosinophils and is produced by Th2 cells and
ILC2s. A role for IL-5 in eosinophil extracellular trap cell death, ie, a proinflammatory cell …

Eosinophils play a pivotal role in the inflammatory pathology of asthma and have been the
target of new biologic treatments for patients with eosinophilic asthma. Given the central role …

Improved understanding of the contribution of eosinophils to various chronic inflammatory
conditions, most notably allergic asthma, has encouraged development of monoclonal …

Background Three anti–IL-5 pathway–directed therapies are approved for use in patients
with severe eosinophilic asthma (SEA); however, no head-to-head comparison data are …

Elevated numbers of blood and tissue eosinophils are present in allergic diseases and
experimental evidence suggests that eosinophils play an important pathogenic role in these …

Asthma is characterized by episodic, reversible airflow obstruction associated with variable
levels of inflammation. Over the past several decades, there has been an increasing …

Compelling evidence has demonstrated that the eosinophils bring negative biological
outcomes in several diseases, including eosinophilic asthma and hypereosinophilic …

Airway inflammation is considered to be the primary component contributing to the
heterogeneity and severity of airway disorders. Therapeutic efficacies of diverse novel …

Mepolizumab is an anti-interleukin-5 (IL-5) humanized monoclonal antibody that has been
recently approved as an add-on biological treatment for severe eosinophilic asthma, by both …

The role of eosinophils as effector cells in asthma pathogenesis has been questioned since
an anti–interleukin (IL)-5 monoclonal antibody (mepolizumab), which depleted blood and …